Cell cycle-dependent effects of 3,3'-diindolylmethane on proliferation and apoptosis of prostate cancer cells

Journal of Cellular Physiology

Volumn 219, Issue 1, 2009, Pages 94-99

  Chinnakannu, Kannagi ^a   Chen, Di ^b   Li, Yiwei ^b   Wang, Zhiwei ^b   Dou, Q Ping ^b   Reddy, G Prem Veer ^a,b   Sarkar, Fazlul H ^b,c  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KARMANOS CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 INDOLEMETHANOL; 3,3 DIINDOLYLMETHANE; ANDROGEN; ANDROGEN RECEPTOR; CYCLIN DEPENDENT KINASE INHIBITOR 1B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEASOME; PROTEIN BCL 2; UNCLASSIFIED DRUG; CDKN1B PROTEIN, HUMAN; DIINDOLYLMETHANE; INDOLE DERIVATIVE; ISOLEUCINE; SIGNAL PEPTIDE;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME INACTIVATION; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN INDUCTION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; TRANSACTIVATION; CELL LINE; DRUG ANTAGONISM; GENETICS; METABOLISM; PATHOLOGY; PROSTATE TUMOR;

APOPTOSIS; CELL CYCLE; CELL LINE; CELL PROLIFERATION; HUMANS; INDOLES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; ISOLEUCINE; MALE; POLY(ADP-RIBOSE) POLYMERASES; PROSTATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; RECEPTORS, ANDROGEN;

EID: 60849123921     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21650     Document Type: Article

References (39)

1. Anderton MJ, Manson MM, Verschoyle R, Gescher A, Steward WP, Williams ML, Mager DE. 2004. Physiological modeling of formulated and crystalline 3,3'-diindolylmethane pharmacokinetics following oral administration in mice. Drug Metab Dispos 32:632-638.
2. Balk SP, Knudsen KE. 2008. AR, the cell cycle, and prostate cancer. Nucl Recept Signal 6:e001 [Epub]. Bhuiyan MM, Li Y, Banerjee S, Ahmed F, Wang Z, Ali S, Sarkar FH. 2006. Down-regulation of androgen receptor by 3,3'- diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells. Cancer Res 66:10064-10072.
3. Bloom J, Cross FR. 2007. Multiple levels of cyclin specificity in cell-cycle control. Nat Rev Mol Cell Biol 8:149-160.
4. Brew CT, Aronchik I, Hsu JC, Sheen JH, Dickson RB, Bjeldanes LF, Firestone GL. 2006. Indole-3-carbinol activates the ATM signaling pathway independent of DNA damage to stabilize p53 and induce G1 arrest of human mammary epithelial cells. Int J Cancer 118:857-868.
5. Chen CD, Sawyers CL. 2002. NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol Cell Biol 22:2862-2870.
6. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. 2004. Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33-39.
7. Chen JJ, Chou CW, Chang YF, Chen CC. 2008. Proteasome inhibitors enhance TRAIL- induced apoptosis through the intronic regulation of DR5: Involvement of NF-kappaB and reactive oxygen species-mediated p53 activation. J Immunol 180:8030-8039.
8. Chen WJ, Lin JK. 2004. Induction of G1 arrest and apoptosis in human jurkat T cells by pentagalloylglucose through inhibiting proteasome activity and elevating p27Kip1, p21Cip1/WAF1, and Bax proteins. J Biol Chem 279:13496-13505.
9. Chinni SR, Sarkar FH. 2002. Akt inactivation is a key event in indole-3-carbinol-induced apoptosis in PC-3 cells. Clin Cancer Res 8:1228-1236.
10. Chu IM, Hengst L, Slingerland JM. 2008. The Cdk inhibitor p27 in human cancer: Prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 8:253-267.
11. Cifuentes E, Croxen R, Menon M, Barrack ER, Reddy GP. 2003. Synchronized prostate cancer cells for studying androgen regulated events in cell cycle progression from G1 into S phase. J Cell Physiol 195:337-345.
12. Cohen JH, Kristal AR, Stanford JL. 2000. Fruit and vegetable intakes and prostate cancer risk. J Natl Cancer Inst 92:61-68.
13. Daniel KG, Chen D, Yan B, Dou QP. 2007. Copper-binding compounds as proteasome inhibitors and apoptosis inducers in human cancer. Front Biosci 12:135-144.
14. Domingo-Domenech J, Pippa R, Tapia M, Gascon P, Bachs O, Bosch M. 2008. Inactivation of NF-kappaB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells. Breast Cancer Res Treat 112:53-62.
15. Ge X, Yannai S, Rennert G, Gruener N, Fares FA. 1996. 3,3'-Diindolylmethane induces apoptosis in human cancer cells. Biochem Biophys Res Commun 228:153-158.
16. Heinlein CA, Chang C. 2004. Androgen receptor in prostate cancer. Endocr Rev 25:276-308.
17. Kong D, Li Y, Wang Z, Banerjee S, Sarkar FH. 2007. Inhibition of angiogenesis and invasion by
18. 3, 3'-diindolylmethane is mediated by NF-kappaB downstream target genes MMP-9 and uPA regulated bioavailability of VEGF in prostate cancer. Cancer Res 67:3310-3319.
19. Lee SO, Lou W, Nadiminty N, Lin X, Gao AC. 2005. Requirement for NF-(kappa)B in interleukin-4-induced androgen receptor activation in prostate cancer cells. Prostate 64:160-167.
20. Li Y, Chinni SR, Sarkar FH. 2005. Selective growth regulatory and pro-apoptotic effects of DIM is mediated by AKT and NF-kappaB pathways in prostate cancer cells. Front Biosci 10:236-243.
21. Li Y, Li X, Sarkar FH. 2003. Gene expression profiles of I3C- and DIM-treated PC3 human prostate cancer cells determined by cDNA microarray analysis. J Nutr 133:1011-1019.
22. Li Y, Wang Z, Kong D, Murthy S, Dou QP, Sheng S, Reddy GP, Sarkar FH. 2007. Regulation of FOXO3a/beta-catenin/GSK-3beta signaling by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells. J Biol Chem 282:21542-21550.
23. Mohler JL, Gregory CW, Ford OH III, Kim D, Weaver CM, Petrusz P, Wilson EM, French FS. 2004. The androgen axis in recurrent prostate cancer. Clin Cancer Res 10:440-448.
24. Nachshon-Kedmi M, Yannai S, Fares FA. 2004. Induction of apoptosis in human prostate cancer cell line, PC3, by 3,3'-diindolylmethane through the mitochondrial pathway. Br J Cancer 91:1358-1363.
25. Nachshon-Kedmi M, Yannai S, Haj A, Fares FA. 2003. Indole-3-carbinol and 3,3'- diindolylmethane induce apoptosis in human prostate cancer cells. Food Chem Toxicol 41:745-752.
26. Nam S, Smith DM, Dou QP. 2001. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem 276:13322-13330.
27. Naujokat C, Hoffmann S. 2002. Role and function of the 26S proteasome in proliferation and apoptosis. Lab Invest 82:965-980.
28. Nencioni A, Grunebach F, Patrone F, Ballestrero A, Brossart P. 2007. Proteasome inhibitors: Antitumor effects and beyond. Leukemia 21:30-36.
29. Nickeleit I, Zender S, Sasse F, Geffers R, Brandes G, Sorensen I, Steinmetz H, Kubicka S, Carlomagno T, Menche D, Gutgemann I, Buer J, Gossler A, Manns MP, Kalesse M, Frank R, Malek NP. 2008. Argyrin a reveals a critical role for the tumor suppressor protein p27(kip1) in mediating antitumor activities in response to proteasome inhibition. Cancer Cell 14:23-35.
30. Orlowski RZ, Kuhn DJ. 2008. Proteasome inhibitors in cancer therapy: Lessons from the first decade. Clin Cancer Res 14:1649-1657.
31. Pelley RP, Chinnakannu K, Murthy S, Strickland FM, Menon M, Dou QP, Barrack ER, Reddy GP. 2006. Calmodulin-androgen receptor (AR) interaction: Calcium-dependent, calpain- mediated breakdown of AR in LNCaP prostate cancer cells. Cancer Res 66:11754-11762.
32. Tanaka K, Kawakami T, Tateishi K, Yashiroda H, Chiba T. 2001. Control of IkappaBalpha proteolysis by the ubiquitin-proteasome pathway. Biochimie 83:351-356.
33. Tavani A, La VC. 1995. Fruit and vegetable consumption and cancer risk in a Mediterranean population. Am J Clin Nutr 61:1374S-1377S.
34. Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. 2005. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 11:4653-4657.
35. Verhoeven DT, Verhagen H, Goldbohm RA, van den Brandt PA, van PG. 1997. A review of mechanisms underlying anticarcinogenicity by brassica vegetables. Chem Biol Interact 103:79-129.
36. Voorhees PM, Dees EC, O'Neil B, Orlowski RZ. 2003. The proteasome as a target for cancer therapy. Clin Cancer Res 9:6316-6325.
37. Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH, Hung MC. 2000. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 60:6841-6845.
38. Yang H, Landis-Piwowar KR, Lu D, Yuan P, Li L, Reddy GP, Yuan X, Dou QP. 2008. Pristimerin induces apoptosis by targeting the proteasome in prostate cancer cells. J Cell Biochem 103:234-244.
39. Zhang J, Hsu BAJ, Kinseth BAM, Bjeldanes LF, Firestone GL. 2003. Indole-3-carbinol induces a G1 cell cycle arrest and inhibits prostate-specific antigen production in human LNCaP prostate carcinoma cells. Cancer 98:2511-2520.